The type I interferonopathies: 10 years on

YJ Crow, DB Stetson - Nature Reviews Immunology, 2022 - nature.com
As brutally demonstrated by the COVID-19 pandemic, an effective immune system is
essential for survival. Developed over evolutionary time, viral nucleic acid detection is a …

Emerging concepts of type I interferons in SLE pathogenesis and therapy

A Psarras, M Wittmann, EM Vital - Nature reviews Rheumatology, 2022 - nature.com
Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …

Human life within a narrow range: The lethal ups and downs of type I interferons

YJ Crow, JL Casanova - Science immunology, 2024 - science.org
The past 20 years have seen the definition of human monogenic disorders and their
autoimmune phenocopies underlying either defective or enhanced type I interferon (IFN) …

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition

Y Luo, M Alexander, M Gadina, JJ O'Shea… - Journal of Allergy and …, 2021 - Elsevier
Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …

[HTML][HTML] DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes

AMS Giordano, M Luciani, F Gatto… - Journal of Experimental …, 2022 - rupress.org
Aberrant induction of type I IFN is a hallmark of the inherited encephalopathy Aicardi-
Goutières syndrome (AGS), but the mechanisms triggering disease in the human central …

JAK: not just another kinase

RP Agashe, SM Lippman, R Kurzrock - Molecular cancer therapeutics, 2022 - AACR
The JAK/STAT axis is implicated in cancer, inflammation, and immunity. Numerous
cytokines/growth factors affect JAK/STAT signaling. JAKs (JAK1, JAK2, JAK3, and TYK 2) …

The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of …

KC Gedik, L Lamot, M Romano, E Demirkaya… - Annals of the …, 2022 - ard.bmj.com
Objective Autoinflammatory type I interferonopathies, chronic atypical neutrophilic
dermatosis with lipodystrophy and elevated temperature/proteasome-associated …

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19

T Bieber, E Feist, AD Irvine, M Harigai, E Haladyj… - Advances in …, 2022 - Springer
Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases

W Damsky, D Peterson, J Ramseier… - Journal of Allergy and …, 2021 - Elsevier
Autoimmune and inflammatory diseases are common and diverse, and they can affect
nearly any organ system. Much of the pathogenesis of these diseases is related to …

Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies

T Armangué, G Olivé-Cirera, E Martínez-Hernandez… - Brain, 2023 - academic.oup.com
Patients with herpes simplex virus (HSV) encephalitis (HSE) often develop neuronal
autoantibody-associated encephalitis (AE) post-infection. Risk factors of AE are unknown …